Insights into Treating Lupus - A Rheum Survey 

Save

RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.

EULAR26: GLP-1 Agonist Use in the RISE Registry

Save

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

ICYMI: VEXAS Syndrome - A Review

Save

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis

Save

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

Spotlight on Comorbidities from EULAR 2026

Save

Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of

ICYMI: EGPA Review

Save

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Save

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

ICYMI: B Cells at the Brink in Sjögren Disease

Save

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

EULAR26: Reports on Systemic Sclerosis

Save

In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).

Brenda McShan: The Creative Heart of RheumNow

Save

A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.

Generic Tofacitinib (6.26.2026)

Save

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

EULAR26: Updates in SLE and APS

Save

Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.